Clinical Trial Detail

NCT ID NCT01886859
Title Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prolymphocytic leukemia

CLL/SLL

Therapies

Ibrutinib + Lenalidomide

Age Groups: adult

No variant requirements are available.